Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In Vivo

An ability to activate latent human immunodeficiency virus type 1 (HIV-1) expression could benefit many HIV cure strategies; however, most latency-reversing agents (LRAs) have proven disappointing. We evaluated AKT/mTOR activators as a potential new class of LRAs. Two glycogen synthase kinase-3 inhi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Virol
Main Authors: Gramatica, Andrea, Schwarzer, Roland, Brantley, William, Varco-Merth, Benjamin, Sperber, Hannah S., Hull, Philip A., Montano, Mauricio, Migueles, Stephen A., Rosenthal, Danielle, Hogan, Louise E., Johnson, Jeffrey R., Packard, Thomas A., Grimmett, Zachary W., Herzig, Eytan, Besnard, Emilie, Nekorchuk, Michael, Hsiao, Feng, Deeks, Steven G., Snape, Michael, Kiernan, Bernard, Roan, Nadia R., Lifson, Jeffrey D., Estes, Jacob D., Picker, Louis J., Verdin, Eric, Krogan, Nevan J., Henrich, Timothy J., Connors, Mark, Ott, Melanie, Pillai, Satish K., Okoye, Afam A., Greene, Warner C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2021
Assuntos:
Vaccines and Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8103695/
https://ncbi.nlm.nih.gov/pubmed/33536176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.02393-20
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados